TP53 and acute myeloid leukemia: Additionally, TP53-mutated MDS and AML are characterized by cytokine dysregulation, immune suppression through regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and metabolic reprogramming, including increased glycolysis and fatty acid metabolism.